Insider · CIK 0001317678
W Bradford Smith
Files at LYRA (Lyra Therapeutics, Inc.). First filing -, latest -.
In brief
W Bradford Smith files SEC Form 4 as director at LYRA (Lyra Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; W Bradford Smith has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 14, 2026 | LYRA Lyra Therapeutics, Inc. | DDisposition to issuer Common Stock | -640 | $0.00 | $0 | 0 | May 15, 2026 |
| May 14, 2025 | LYRA Lyra Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +32,000 | $0.00 | $0 | 32,000 | May 16, 2025 |
Questions about W Bradford Smith
Answered from the filings on this page, as of the latest one.
Is W Bradford Smith buying or selling?
W Bradford Smith has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did W Bradford Smith's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and W Bradford Smith has 0.
Where does W Bradford Smith file Form 4?
W Bradford Smith has filed Form 4 at LYRA (Lyra Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.